Updates in the treatment of multiple myeloma

摘要

JB Current reports have demonstrated an extension in survival by 2-3 years, from an average of 3-5 years to at least 5-7 years. We recently published a retrospective review of 300 multiple myeloma patients treated with zoledronic acid who showed a 5-year survival of 69% and median overall survival (OS) of nearly 11 years (131 months). We are currently updating data from our own patients, and I anticipate even greater survival improvements once the final results are in.